Biography: Dr. Knight currently serves as Chairman of the Board of Directors for FORUM Pharmaceuticals. He joined Fidelity BioSciences, a healthcare venture firm owned by Fidelity, in 2003 as President and Managing Partner. He has worked in the pharmaceutical and biotechnology industries for more than 20 years. Prior to joining Fidelity, Dr. Knight was President and Chief Operating Officer for EPIX Pharmaceuticals in Cambridge, Massachusetts. Before joining EPIX, Dr. Knight worked at Arthur D. Little Inc., specializing in mergers and acquisitions in the pharmaceutical industry, and performed research at AT&T Bell Laboratories, the National Institutes of Health, and Yale University.

Dr. Knight serves on the Board of Directors of Innovent Biologics, Inc., Proteostasis Therapeutics, Iora Health, Blueprint Medicines, Pulmocide, and Optegra Global Ltd. Dr. Knight previously served on the boards of several private and public healthcare companies including FoldRx (acquired by Pfizer) Ironwood Pharmaceuticals (NASDAQ: IRWD), NextWave Pharmaceuticals (acquired by Pfizer), and Respivert, Ltd. (acquired by J&J).

Education: Dr. Knight holds an MD from the Yale University School of Medicine and an MBA from the Yale School of Organization and Management. Dr. Knight also earned a BS in biology from Columbia University, graduating summa cum laude and Phi Beta Kappa.

Biography: Dr. Carpenter has more than 25 years of experience in medicine, basic science and clinical research, and pharmaceutical drug development. His experience in the pharmaceutical and biotechnology industries includes Co-Founder, President, and CEO of Seaside Therapeutics, President and CEO of Sention, VP of Clinical Research & Development and Regulatory Affairs at Adolor Corporation, and member of Astra Pain Control’s Global Therapeutic Area Team. Dr. Carpenter has broad experience leading pharmaceutical research and development teams, having submitted a number of INDs, NDAs, and sNDAs. Prior to joining industry, he held academic faculty appointments at Virginia Mason Medical Center and Wake Forest University, where he specialized in anesthesiology and pain medicine. He has co-authored 65 journal articles and 7 patents and has served as editor-in-chief on the editorial boards of 4 medical journals. Dr. Carpenter is currently a member of National Advisory Mental Health Council and the Scientific Advisory Board of EU-AIMS.

Education: Dr. Carpenter is board certified in anesthesiology and pain management. He has completed a fellowship in pharmacokinetics at the University of California, San Francisco, and a sabbatical in molecular biology at the University of Washington.

Biography: Deborah Dunsire is an industry leader who brings more than 25 years of scientific, clinical, operational, and commercial experience, and proven leadership in the biotechnology and pharmaceutical industries.

Prior to joining FORUM Pharmaceuticals in 2013, she served as President and Chief Executive Officer of Millennium Pharmaceuticals, Inc., now Millennium: The Takeda Oncology Company, from 2005 to 2013. During that period, she transformed the company into a biotechnology industry leader by focusing R&D, driving the development pipeline, fostering a culture of employee engagement, increasing the commercial mind-set across the organization, and crafting highly effective partnerships to drive the company’s growth. Millennium was acquired by Takeda Pharmaceutical Company Limited in 2008 for $8.8 billion, one of the largest biotech acquisitions at that time.

Deborah was the first woman appointed to the board of Takeda Pharmaceuticals Limited in Japan. Prior to this, Deborah led the Novartis Oncology Business in North America, playing a critical role in the broad development and successful launch of a number of products, increasing revenues from $50 million to more than $2.2 billion.

Currently, Deborah is a board member of Allergan, Inc., and the Biotechnology Industry Organization (BIO). She is a trustee of the Museum of Science (Boston) and a member of the Massachusetts General Hospital Research Advisory Council. She has received numerous awards, including the 2001 American Cancer Society Excalibur Award, the 2009 Healthcare Businesswomen’s Association’s “Woman of the Year,” the 2011 MassBIO Innovator Award, and the 2013 Boston CEO Conference Lifetime Achievement Award.

Education: Deborah received her medical degree from the University of Witwatersrand, Johannesburg, South Africa.

Biography: John J. Remondi is Executive Vice President of Fidelity Investments, a leading provider of investment management, retirement planning, portfolio guidance, brokerage, benefits outsourcing, and other financial products and services to more than 20 million individuals, institutions, and financial intermediaries.

Mr. Remondi reports to Chairman Edward C. Johnson 3^rd He is a member of the Board of Directors of FMR LLC, the holding company for the businesses of Fidelity Investments; Chairman of the FMR LLC Audit Committee; and member of its Compensation Committee. He is also a board member of Fidelity Financial Services; Devonshire Investors; Pro-Build Holdings, Inc.; FORUM Pharmaceuticals; and several non-profit boards.

Prior to assuming his current role, Mr. Remondi served as President of Fidelity Investors Management LLC (FIML) from May 1998 to August 2003. FIML provides investment advisory and supervision services for several Fidelity employee-owned investment partnerships and principally invests equity in a broad range of private equity companies, as well as real estate. Prior to this role, he was Managing Director of Fidelity Ventures, the venture capital arm of Fidelity Investment. Mr. Remondi joined Fidelity in 1983 as Chief Financial Officer for FMR Corp. and served in the position until joining Fidelity Capital/Ventures in 1991.

Prior to joining Fidelity, Mr. Remondi was Vice President and Chief Financial Officer at Haemonetics Corporation and Vice President of Finance and Group Controller at Merriman/Litton Industries.

Education: Mr. Remondi received a BS degree in accounting from Boston College in 1960 and an MBA from Boston University in 1963.

Biography: Ms. Uhrig was an analyst and fund manager at Fidelity Investments for 22 years. Since retiring from professional money management in 2009, she has served in an advisory role at Fidelity and now sits on the boards of Geode Capital Management and FORUM Pharmaceuticals, both fully owned Fidelity subsidiaries. Ms. Uhrig began her career at Fidelity in 1987 as a research analyst before becoming a diversified fund manager in Fidelity’s Growth Group in 1993. Over the course of her career, she managed several funds including the Fidelity Mid-Cap Stock Fund, the Fidelity Advisor Mid-Cap Stock Fund, the Fidelity Advisor Equity Growth Fund, the Fidelity VIP: Growth Fund, and the Fidelity Blue Chip Growth Portfolio. She managed assets of up to $38 billion and outperformed the relevant benchmark during her tenure on all of her funds. She also managed the Fidelity Foundations for 5 years. Prior to joining Fidelity, Ms. Uhrig was a research associate for Fred Alger Management, in New York, from 1983 to 1985. Ms. Uhrig is a member of the Board of Overseers of the Tuck School of Business at Dartmouth College, the Board of Trustees of the New England Conservatory, and the Board of Trustees of the Massachusetts Eye and Ear Infirmary.

Education: She earned a BA degree in government from Harvard College, cum laude, in 1983 and an MBA from the Tuck School at Dartmouth College in 1987.

Biography: Dr. Weisskoff has worked extensively in both academia and the bioscience industry for more than 25 years. Prior to joining Fidelity in 2004, he held various senior roles in R&D and Business Development at both pharmaceutical and medical device companies. In his academic career, Dr. Weisskoff was Associate Professor of Radiology at Harvard Medical School, on the faculty of the Harvard-MIT Health Sciences Technology (HST) Program, and performed research at Massachusetts General Hospital, where he was Associate Director of the MGH-NMR Center. There he worked at the intersection of basic research, medical technology development, and clinical research in a variety of areas. Robert is the author of more than 100 peer-reviewed scientific papers and an inventor on 6 US patents.

Dr. Weisskoff has served on the boards of Accuri Cytometers, Amphora Medical, Bioconnect Systems, Ikano Therapeutics, Laurus Labs, Tetraphase, Topaz, Trivitron Healthcare, Theia, Transave, ViewRay, Xcyton Diagnostics, and FORUM Pharmaceuticals.

Education: Dr. Weisskoff holds a PhD in physics from the Massachusetts Institute of Technology and an MBA from Columbia University. He received his AB degree in physics from Harvard University, graduating magna cum laude and Phi Beta Kappa.